Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Nand Kishore Singh
Observed names:
N Singh,
N.K. Singh,
Nand Singh
Institution:
Quotient Sciences Limited (United Kingdom)
Observed institutions:
Institute of Human Behaviour and Allied Sciences,
Shri Guru Ram Rai Institute of Medical & Health Sciences,
Quotient Sciences Limited (United Kingdom)
ORCID:
0009-0000-6683-7450
Observed ORCID:
0009-0000-6683-7450
OpenAlex ID:
A5109407617
Role of pharmaco-epidemiology in psychopharmacology: a study in psychiatric out-patient department of a tertiary care teaching hospital at Dehradun, Uttarakhand
2014
·
Shaktibala Dutta
, Mirza Beg
, et al.
·
International Journal of Basic & Clinical Pharmacology
·
10
PDF
Absorption, metabolism and excretion of opicapone in human healthy volunteers
2022
·
Ana I. Loureiro
, Francisco Rocha
, et al.
·
British Journal of Clinical Pharmacology
·
9
PDF
First‐in‐human safety, tolerability, pharmacokinetics and pilot food‐effect study of the candidate antimalarial compound MMV367
2025
·
Andrea Kuemmerle
, Nand Singh
, et al.
·
British Journal of Clinical Pharmacology
·
6
PDF
A retrospective analysis of adverse drug reactions in a tertiary care teaching hospital at Dehradun, Uttarakhand
2015
·
Shakti Dutta
, Mirza Beg
, et al.
·
International Journal of Basic & Clinical Pharmacology
·
5
PDF
Amnesia for autobiographical memory: a case series.
2002
·
R K Chadda
, N Singh
, et al.
·
PubMed Central
·
5
PDF
Performance Evaluation of A PV- Powered Alkaline Water Electrolyzer for Sustainable Green Hydrogen Production
2022
·
Nand Kishore Singh
, Seema Saxena
, et al.
·
International Journal of Engineering Trends and Technology
·
4
Pharmacokinetics, Disposition, and Biotransformation of Laroprovstat in Humans: In Vivo and In Vitro Evaluations
2026
·
Xue‐Qing Li
, Marie Elebring
, et al.
·
The Journal of Clinical Pharmacology
·
3
PDF
Generation of frameshift-mutated TGFβR2-specific T cells in healthy subjects following administration with cancer vaccine candidate FMPV-1/GM-CSF in a phase 1 study
2025
·
Else Marit Inderberg
, Nand Singh
, et al.
·
Cancer Immunology Immunotherapy
·
3
Study on drug usage pattern of anxiolytics in psychiatric department in a tertiary care teaching hospital at Dehradun, Uttarakhand, India
2017
·
Shakti B. Dutta
, Mirza A. Beg
, et al.
·
International Journal of Basic & Clinical Pharmacology
·
3
PDF
Recent scenario on psychotropic drug usage pattern among patients attending psychiatric outpatient department of a tertiary care teaching hospital in Nepal
2016
·
Vijay Kaul
, Mirza Beg
, et al.
·
International Journal of Basic & Clinical Pharmacology
·
2
PDF
Safe switch of treatment from the reference product to RGB-02, a proposed biosimilar pegfilgrastim: Analysis of the results of three clinical trials
2018
·
A. Illes
, L. Perjesi
, et al.
·
Annals of Oncology
·
1
Phase I Trial: Quotient Code QSC301409
2025
·
Nand Singh
·
http://isrctn.com/
A study in healthy volunteers to assess how the test medicine (IB1001) affects how the body takes up Digoxin and Rosuvastatin (Part 1) and how food affects blood levels of IB1001 (Part 2)
2025
·
Taylor Fields
, Nand Singh
·
http://isrctn.com/
Phase I Trial: Quotient code QSC206231
2024
·
Nand Singh
, Andreas Schatzlein
, et al.
·
http://isrctn.com/
Phase I Trial Quotient code: QSC302573
2024
·
Nand Singh
·
http://isrctn.com/
A study in healthy volunteers to assess how the test medicine ODM-111 is taken up, broken down and removed from the body when taken by mouth as a tablet, and when given radiolabelled in the form of an oral solution and by short infusion into a vein
2024
·
Nand Singh
·
http://isrctn.com/
Phase I Trial: Quotient Code QSC300787
2024
·
Nand Singh
·
http://isrctn.com/
Phase I Trial: Quotient Code QSC300687
2024
·
Nand Singh
, Kavita Dhamdhere
·
http://isrctn.com/
Phase I trial: Quotient code QSC300553
2024
·
Nand Singh
, William Waverczak
, et al.
·
http://isrctn.com/
Phase I trial, Quotient Code: QSC300414
2023
·
Nand Singh
, Fabrizio Giordanetto
, et al.
·
http://isrctn.com/
Phase I Trial: Quotient Code QSC300535
2023
·
Nand Singh
, Marie Bengtson
, et al.
·
http://isrctn.com/
Phase I Trial, Quotient Code: QSC207970
2023
·
Nand Singh
, Regulatory Affairs
, et al.
·
http://isrctn.com/
Phase I Trial, Quotient Code: QSC206367
2022
·
Nand Singh
, Regulatory Affairs
, et al.
·
http://isrctn.com/
Phase I Trial, Quotient code: QSC205599
2022
·
Nand Singh
·
http://isrctn.com/
Phase I Trial, Quotient Code: QSC206321
2022
·
Nand Singh
, Regulatory Affairs
, et al.
·
http://isrctn.com/
Show more works
View as search
Works count:
28
Citation count:
51
H-index:
5
I10-index:
1
Year
Topic
Type
